Aarti Drugs Ltd

Aarti Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Aarti Drugs Ltd

₹ 420 19.99%
07 May - close price
aartidrugs.com BSE: 524348 NSE: AARTIDRUGS
About

Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations. [1]

It is exporting its API's and Speciality chemicals to over 100 countries across the globe. [2]

Key Points

Market Leadership
The company is a leading global producer of 50+ API molecules across categories like antibiotics, antiprotozoal, anti-inflammatory, anti-diabetic, and anti-fungal. It is the largest manufacturer of Fluoroquinolones, Tinidazole, Metronidazole Benzoate, Celecoxib, Nimesulide, and Ketoconazole worldwide, and among the top producers of Metformin globally. [1] [2]

Website BSE NSE
  • Market Cap ₹ 3,862 Cr.
  • Current Price ₹ 420
  • High / Low ₹ 635 / 312
  • Stock P/E 23.0
  • Book Value ₹ 149
  • Dividend Yield 0.24 %
  • ROCE 12.9 %
  • ROE 12.7 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Stock is trading at 2.82 times its book value
  • The company has delivered a poor sales growth of 5.74% over past five years.
  • Company has a low return on equity of 13.8% over last 3 years.
  • Company might be capitalizing the interest cost
  • Dividend payout has been low at 5.45% of profits over last 3 years
  • Promoter holding has decreased over last 3 years: -4.35%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Part of BSE Allcap BSE SmallCap BSE Healthcare Nifty Total Market Nifty Microcap 250

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
694 622 688 664 742 661 642 606 620 555 598 557 677
608 555 613 593 649 577 565 536 534 490 531 495 583
Operating Profit 86 67 74 71 94 84 76 70 86 65 67 62 93
OPM % 12% 11% 11% 11% 13% 13% 12% 12% 14% 12% 11% 11% 14%
3 0 0 1 1 1 1 2 1 1 1 12 2
Interest 6 7 8 9 9 9 8 8 9 9 9 9 9
Depreciation 13 13 13 13 12 13 13 13 14 13 14 14 15
Profit before tax 70 48 53 50 73 64 56 52 64 44 46 51 71
Tax % 22% 28% 27% 26% 23% 24% 30% 29% 26% 24% 24% 27% 12%
55 35 39 37 56 48 40 37 47 33 35 37 63
EPS in Rs 5.98 3.76 4.18 3.96 6.06 5.17 4.31 3.99 5.15 3.62 3.81 4.03 6.84
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
501 1,097 1,140 1,195 1,244 1,561 1,806 2,155 2,489 2,716 2,529 2,387
432 925 960 1,005 1,042 1,350 1,541 1,714 2,156 2,407 2,208 2,100
Operating Profit 69 172 180 190 202 211 266 440 333 309 321 287
OPM % 14% 16% 16% 16% 16% 14% 15% 20% 13% 11% 13% 12%
0 1 0 4 1 6 6 5 11 2 4 16
Interest 17 42 48 40 38 44 37 26 24 37 38 36
Depreciation 19 31 37 38 40 43 49 50 50 50 51 56
Profit before tax 33 100 95 116 125 131 185 369 270 224 236 212
Tax % 29% 23% 28% 29% 34% 32% 24% 24% 24% 26% 27% 21%
24 77 69 82 82 90 141 280 205 166 172 168
EPS in Rs 2.46 7.97 7.09 8.57 8.73 9.52 15.17 30.09 22.14 17.96 18.65 18.29
Dividend Payout % 25% 41% 24% 3% 3% 3% 3% 8% 5% 6% 5% 5%
Compounded Sales Growth
10 Years: 8%
5 Years: 6%
3 Years: -1%
TTM: -6%
Compounded Profit Growth
10 Years: 8%
5 Years: 4%
3 Years: -6%
TTM: -2%
Stock Price CAGR
10 Years: 9%
5 Years: 17%
3 Years: -2%
1 Year: -12%
Return on Equity
10 Years: 19%
5 Years: 18%
3 Years: 14%
Last Year: 13%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 12 24 24 24 24 24 23 93 93 93 92 91
Reserves 151 284 333 376 432 520 629 820 944 1,100 1,190 1,278
267 448 483 480 546 507 389 351 543 609 564 615
93 248 261 311 388 405 535 502 629 620 587 591
Total Liabilities 523 1,004 1,102 1,191 1,389 1,455 1,576 1,766 2,208 2,421 2,432 2,575
248 448 493 581 602 625 644 665 690 676 811 866
CWIP 10 16 34 14 28 33 12 19 77 210 261 330
Investments 5 5 5 12 11 12 13 17 19 19 20 22
260 534 570 584 748 785 907 1,064 1,422 1,516 1,340 1,356
Total Assets 523 1,004 1,102 1,191 1,389 1,455 1,576 1,766 2,208 2,421 2,432 2,575

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
21 105 133 175 70 143 251 155 70 133 359 245
-76 -107 -99 -107 -74 -62 -33 -72 -150 -164 -224 -165
53 1 -33 -68 4 -80 -215 -81 92 17 -136 -82
Net Cash Flow -3 -1 1 -0 0 1 2 2 13 -14 -1 -2

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 88 105 106 91 110 107 99 94 110 116 102 115
Inventory Days 103 82 86 100 132 86 102 117 115 101 107 112
Days Payable 73 83 90 94 123 85 104 93 103 94 94 98
Cash Conversion Cycle 118 104 103 97 119 109 97 118 123 123 115 128
Working Capital Days 134 98 102 97 122 105 87 110 122 126 116 126
ROCE % 13% 18% 18% 17% 17% 21% 34% 21% 15% 15% 13%

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
59.98% 59.77% 59.66% 59.57% 58.70% 58.57% 57.47% 57.13% 55.67% 55.64% 55.38% 55.48%
2.07% 1.94% 1.90% 1.94% 1.97% 2.33% 2.10% 2.56% 2.95% 2.50% 2.28% 2.25%
2.76% 3.16% 3.90% 4.09% 4.72% 5.32% 5.26% 5.99% 7.35% 7.83% 8.77% 9.70%
35.19% 35.11% 34.53% 34.39% 34.63% 33.78% 35.16% 34.30% 34.01% 34.01% 33.58% 32.57%
No. of Shareholders 1,86,6741,80,3031,73,2831,69,0901,62,4091,67,4461,70,4141,57,5471,50,2181,90,2811,76,0061,69,761

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls